Association of Breast and Ovarian Cancers With Predisposition Genes Identified by Large-Scale Sequencing

Importance Since the discovery of BRCA1 and BRCA2, multiple high- and moderate-penetrance genes have been reported as risk factors for hereditary breast cancer, ovarian cancer, or both; however, it is unclear whether these findings represent the complete genetic landscape of these cancers. Systematic investigation of the genetic contributions to breast and ovarian cancers is needed to confirm these findings and explore potentially new associations. Objective To confirm reported and identify additional predisposition genes for breast or ovarian cancer. Design, Setting, and Participants In this sample of 11 416 patients with clinical features of breast cancer, ovarian cancer, or both who were referred for genetic testing from 1200 hospitals and clinics across the United States and of 3988 controls who were referred for genetic testing for noncancer conditions between 2014 and 2015, whole-exome sequencing was conducted and gene-phenotype associations were examined. Case-control analyses using the Genome Aggregation Database as a set of reference controls were also conducted. Main Outcomes and Measures Breast cancer risk associated with pathogenic variants among 625 cancer predisposition genes; association of identified predisposition breast or ovarian cancer genes with the breast cancer subtypes invasive ductal, invasive lobular, hormone receptor–positive, hormone receptor–negative, and male, and with early-onset disease. Results Of 9639 patients with breast cancer, 3960 (41.1%) were early-onset cases (⩽45 years at diagnosis) and 123 (1.3%) were male, with men having an older age at diagnosis than women (mean [SD] age, 61.8 [12.8] vs 48.6 [11.4] years). Of 2051 women with ovarian cancer, 445 (21.7%) received a diagnosis at 45 years or younger. Enrichment of pathogenic variants were identified in 4 non-BRCA genes associated with breast cancer risk: ATM (odds ratio [OR], 2.97; 95% CI, 1.67-5.68), CHEK2 (OR, 2.19; 95% CI, 1.40-3.56), PALB2 (OR, 5.53; 95% CI, 2.24-17.65), and MSH6 (OR, 2.59; 95% CI, 1.35-5.44). Increased risk for ovarian cancer was associated with 4 genes: MSH6 (OR, 4.16; 95% CI, 1.95-9.47), RAD51C (OR, not estimable; false-discovery rate–corrected P = .004), TP53 (OR, 18.50; 95% CI, 2.56-808.10), and ATM (OR, 2.85; 95% CI, 1.30-6.32). Neither the MRN complex genes nor CDKN2A was associated with increased breast or ovarian cancer risk. The findings also do not support previously reported breast cancer associations with the ovarian cancer susceptibility genes BRIP1, RAD51C, and RAD51D, or mismatch repair genes MSH2 and PMS2. Conclusions and Relevance The results of this large-scale exome sequencing of patients and controls shed light on both well-established and controversial non-BRCA predisposition gene associations with breast or ovarian cancer reported to date and may implicate additional breast or ovarian cancer susceptibility gene candidates involved in DNA repair and genomic maintenance.

[1]  F. Couch,et al.  Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls. , 2017, Gynecologic oncology.

[2]  Robert Huether,et al.  Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer , 2017, JAMA oncology.

[3]  E. Ostrander,et al.  Rare, protein-truncating variants in ATM, CHEK2 and PALB2, but not XRCC2, are associated with increased breast cancer risks , 2017, Journal of Medical Genetics.

[4]  Alexander Gutin,et al.  Breast and Ovarian Cancer Penetrance Estimates Derived From Germline Multiple-Gene Sequencing Results in Women. , 2017, JCO precision oncology.

[5]  Jefferey Chen,et al.  Sanger Confirmation Is Required to Achieve Optimal Sensitivity and Specificity in Next-Generation Sequencing Panel Testing. , 2016, The Journal of molecular diagnostics : JMD.

[6]  Seunggeun Lee,et al.  Improving power for rare variant tests by integrating external controls , 2016, bioRxiv.

[7]  E. Winer,et al.  Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  E. Thompson,et al.  Panel Testing for Familial Breast Cancer: Calibrating the Tension Between Research and Clinical Care. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Mark E. Robson,et al.  Counselling framework for moderate-penetrance cancer-susceptibility mutations , 2016, Nature Reviews Clinical Oncology.

[10]  F. Nielsen,et al.  Hereditary breast and ovarian cancer: new genes in confined pathways , 2016, Nature Reviews Cancer.

[11]  T. Walsh,et al.  Inherited Mutations in Women With Ovarian Carcinoma. , 2016, JAMA oncology.

[12]  S. Cross,et al.  No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing , 2016, Journal of Medical Genetics.

[13]  Li Ding,et al.  Patterns and functional implications of rare germline variants across 12 cancer types , 2015, Nature Communications.

[14]  Ricardo Villamarín-Salomón,et al.  ClinVar: public archive of interpretations of clinically relevant variants , 2015, Nucleic Acids Res..

[15]  Lara E Sucheston-Campbell,et al.  Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. , 2015, Journal of the National Cancer Institute.

[16]  Lara E Sucheston-Campbell,et al.  Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Geoffrey B. Nilsen,et al.  A Systematic Comparison of Traditional and Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Genes in More Than 1000 Patients. , 2015, The Journal of molecular diagnostics : JMD.

[18]  Nazneen Rahman,et al.  Gene-panel sequencing and the prediction of breast-cancer risk. , 2015, The New England journal of medicine.

[19]  A. Toss,et al.  Hereditary Ovarian Cancer: Not Only BRCA 1 and 2 Genes , 2015, BioMed research international.

[20]  L. Dossus,et al.  Lobular breast cancer: incidence and genetic and non-genetic risk factors , 2015, Breast Cancer Research.

[21]  H. Rehm,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[22]  R. Redon,et al.  Testing the burden of rare variation in arrhythmia-susceptibility genes provides new insights into molecular diagnosis for Brugada syndrome. , 2015, Human molecular genetics.

[23]  Brigitte Rack,et al.  Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  B. Fridley,et al.  The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population. , 2014, Human molecular genetics.

[25]  J. Hopper,et al.  Rare key functional domain missense substitutions in MRE11A, RAD50, and NBN contribute to breast cancer susceptibility: results from a Breast Cancer Family Registry case-control mutation-screening study , 2014, Breast Cancer Research.

[26]  Nazneen Rahman,et al.  Realizing the promise of cancer predisposition genes , 2014, Nature.

[27]  Nicholas Katsanis,et al.  Molecular genetic testing and the future of clinical genomics , 2013, Nature Reviews Genetics.

[28]  Florentia Fostira,et al.  Hereditary Breast Cancer: The Era of New Susceptibility Genes , 2013, BioMed research international.

[29]  S. Seal,et al.  Germline RAD51C mutations confer susceptibility to ovarian cancer , 2012, Nature Genetics.

[30]  Wei Pan,et al.  Comparison of statistical tests for disease association with rare variants , 2011, Genetic epidemiology.

[31]  Rochelle L. Garcia,et al.  Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing , 2011, Proceedings of the National Academy of Sciences.

[32]  Deborah Hughes,et al.  Germline mutations in RAD51D confer susceptibility to ovarian cancer , 2011, Nature Genetics.

[33]  Laetitia Huiart,et al.  Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. , 2011, JAMA.

[34]  J. Klijn,et al.  Association of rare MSH6 variants with familial breast cancer , 2010, Breast Cancer Research and Treatment.

[35]  Finlay Macrae,et al.  Risks of Lynch syndrome cancers for MSH6 mutation carriers. , 2010, Journal of the National Cancer Institute.

[36]  W. Thilly,et al.  A strategy to discover genes that carry multi-allelic or mono-allelic risk for common diseases: a cohort allelic sums test (CAST). , 2007, Mutation research.

[37]  S. Seal,et al.  PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene , 2007, Nature Genetics.

[38]  Nazneen Rahman,et al.  Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles , 2006, Nature Genetics.

[39]  Nazneen Rahman,et al.  ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles , 2006, Nature Genetics.

[40]  S. Narod,et al.  A common variant of CDKN2A (p16) predisposes to breast cancer , 2005, Journal of Medical Genetics.

[41]  Nazneen Rahman,et al.  CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. , 2004, American journal of human genetics.

[42]  Douglas F. Easton,et al.  Polygenic susceptibility to breast cancer and implications for prevention , 2002, Nature Genetics.

[43]  Å. Borg,et al.  High Frequency of Multiple Melanomas and Breast and Pancreas Carcinomas in CDKN2A Mutation-Positive Melanoma Families , 2000 .

[44]  D. Easton How many more breast cancer predisposition genes are there? , 1999, Breast Cancer Research.